Septerna Inc/$SEPN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Septerna Inc
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
Ticker
$SEPN
Sector
Primary listing
Employees
130
Headquarters
Website
Septerna Inc Metrics
BasicAdvanced
$1.6bn
-
-$0.81
-
-
Price and volume
Market cap
$1.6bn
52-week high
$37.01
52-week low
$9.85
Average daily volume
321k
Financial strength
Current ratio
4.709
Quick ratio
4.627
Long term debt to equity
5.491
Total debt to equity
6.101
Profitability
EBITDA (TTM)
-66.559
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-49.88%
Operating margin (TTM)
-94.37%
Effective tax rate (TTM)
-0.98%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
-8.49%
Return on equity (TTM)
-9.26%
Valuation
Price to revenue (TTM)
21.643
Price to book
4.17
Price to tangible book (TTM)
4.17
Price to free cash flow (TTM)
14.624
Free cash flow yield (TTM)
6.84%
Free cash flow per share (TTM)
2.405
Growth
Revenue change (TTM)
7,295.60%
Earnings per share change (TTM)
-79.18%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs